Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Loss and Comprehensive Loss (Unaudited)

v3.21.2
Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
EXPENSES        
Research and development $ 4,591 $ 1,891 $ 19,460 $ 4,535
General and administrative 2,102 1,863 6,519 5,494
Total operating expenses 6,693 3,754 25,979 10,029
OTHER INCOME (EXPENSE)        
Interest income 3 2 14 47
Other expenses (1) (12) (36) (24)
Total other income (expense) 2 (10) (22) 23
Net loss and comprehensive loss $ (6,691) $ (3,764) $ (26,001) $ (10,006)
Basic and diluted net loss per common share $ (0.71) $ (1.14) $ (3.39) $ (4.55)
Weighted average shares used in computation of basic and diluted net loss per common share 9,452,238 3,289,252 7,670,383 2,197,368